Published in J Virol on September 19, 2012
Genome Sequencing and Analysis of Geographically Diverse Clinical Isolates of Herpes Simplex Virus 2. J Virol (2015) 0.98
Current status and prospects for development of an HSV vaccine. Vaccine (2013) 0.98
Herpes simplex virus type 2 glycoprotein H interacts with integrin αvβ3 to facilitate viral entry and calcium signaling in human genital tract epithelial cells. J Virol (2014) 0.87
A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice. PLoS One (2013) 0.86
The challenge of developing a herpes simplex virus 2 vaccine. Expert Rev Vaccines (2012) 0.85
HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine. Viruses (2014) 0.82
THY-1 Cell Surface Antigen (CD90) Has an Important Role in the Initial Stage of Human Cytomegalovirus Infection. PLoS Pathog (2015) 0.81
Displacement of the C terminus of herpes simplex virus gD is sufficient to expose the fusion-activating interfaces on gD. J Virol (2013) 0.80
Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections. Curr Clin Microbiol Rep (2015) 0.75
A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2. J Virol (2015) 0.75
Intramuscular delivery of replication-defective herpes simplex virus gives antigen expression in muscle syncytia and improved protection against pathogenic HSV-2 strains. Virology (2017) 0.75
Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol (1967) 106.91
The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol (1988) 19.25
Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep (2010) 14.85
Cloning and stable maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based vector. Proc Natl Acad Sci U S A (1992) 13.77
Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res (2005) 11.23
Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS (2006) 10.56
Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell (1996) 9.03
Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science (1998) 7.89
Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med (1983) 7.89
Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1. J Mol Biol (1985) 7.32
Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc Natl Acad Sci U S A (1998) 5.37
Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol (1999) 4.84
Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol Cell (2001) 4.44
Systematic excision of vector sequences from the BAC-cloned herpesvirus genome during virus reconstitution. J Virol (1999) 4.23
Glycoproteins gB, gD, and gHgL of herpes simplex virus type 1 are necessary and sufficient to mediate membrane fusion in a Cos cell transfection system. J Virol (1998) 3.98
Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol (2004) 3.92
An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ (2008) 3.62
Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes (2004) 3.47
Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J Virol (2002) 3.41
The genome sequence of herpes simplex virus type 2. J Virol (1998) 3.39
The DNA sequences of the long repeat region and adjoining parts of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol (1988) 2.50
Genital herpes infection: a review. Int J Epidemiol (1997) 1.84
An acutely and latently expressed herpes simplex virus 2 viral microRNA inhibits expression of ICP34.5, a viral neurovirulence factor. Proc Natl Acad Sci U S A (2008) 1.77
A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9. J Virol (2007) 1.76
Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology (2004) 1.73
Numerous conserved and divergent microRNAs expressed by herpes simplex viruses 1 and 2. J Virol (2010) 1.71
Sequence variability in clinical and laboratory isolates of herpes simplex virus 1 reveals new mutations. J Virol (2010) 1.71
Construction and characterization of bacterial artificial chromosomes containing HSV-1 strains 17 and KOS. J Virol Methods (2006) 1.71
Novel less-abundant viral microRNAs encoded by herpes simplex virus 2 latency-associated transcript and their roles in regulating ICP34.5 and ICP0 mRNAs. J Virol (2008) 1.68
Expression of the herpes simplex virus type 2 latency-associated transcript enhances spontaneous reactivation of genital herpes in latently infected guinea pigs. J Exp Med (1995) 1.63
Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion. J Virol (2005) 1.56
Structure of herpes simplex virus glycoprotein D bound to the human receptor nectin-1. PLoS Pathog (2011) 1.53
Development of a syngenic murine B16 cell line-derived melanoma susceptible to destruction by neuroattenuated HSV-1. Mol Ther (2001) 1.47
Herpes simplex virus gD forms distinct complexes with fusion executors gB and gH/gL in part through the C-terminal profusion domain. J Biol Chem (2009) 1.45
Cloning of the full-length rhesus cytomegalovirus genome as an infectious and self-excisable bacterial artificial chromosome for analysis of viral pathogenesis. J Virol (2003) 1.45
Mutations in herpes simplex virus glycoprotein D that prevent cell entry via nectins and alter cell tropism. Proc Natl Acad Sci U S A (2004) 1.43
Different receptors binding to distinct interfaces on herpes simplex virus gD can trigger events leading to cell fusion and viral entry. Virology (2006) 1.41
Herpes simplex virus type 2 (HSV-2) establishes latent infection in a different population of ganglionic neurons than HSV-1: role of latency-associated transcripts. J Virol (2006) 1.39
Potential nectin-1 binding site on herpes simplex virus glycoprotein d. J Virol (2005) 1.39
Characterization of herpes simplex virus type 2 transcription during latent infection of mouse trigeminal ganglia. J Virol (1990) 1.34
Epidemiology of genital herpes simplex virus infection in developed countries. Herpes (2004) 1.31
Genetic analysis of varicella-zoster virus ORF0 to ORF4 by use of a novel luciferase bacterial artificial chromosome system. J Virol (2007) 1.29
Cloning of the varicella-zoster virus genome as an infectious bacterial artificial chromosome in Escherichia coli. Vaccine (2004) 1.27
Identification of viral microRNAs expressed in human sacral ganglia latently infected with herpes simplex virus 2. J Virol (2009) 1.21
Function of herpes simplex virus type 1 gD mutants with different receptor-binding affinities in virus entry and fusion. J Virol (2003) 1.18
The herpes simplex virus receptor nectin-1 is down-regulated after trans-interaction with glycoprotein D. Virology (2008) 1.17
Infection of neurons and encephalitis after intracranial inoculation of herpes simplex virus requires the entry receptor nectin-1. Proc Natl Acad Sci U S A (2009) 1.16
Genome sequence of herpes simplex virus 1 strain KOS. J Virol (2012) 1.12
Functional characterization of the HveA homolog specified by African green monkey kidney cells with a herpes simplex virus expressing the green fluorescence protein. Virology (1999) 1.12
Crystallization and preliminary diffraction studies of the ectodomain of the envelope glycoprotein D from herpes simplex virus 1 alone and in complex with the ectodomain of the human receptor HveA. Acta Crystallogr D Biol Crystallogr (2002) 1.11
Engineered disulfide bonds in herpes simplex virus type 1 gD separate receptor binding from fusion initiation and viral entry. J Virol (2007) 1.09
Human herpesvirus 6 encoded glycoprotein Q1 gene is essential for virus growth. Virology (2010) 1.07
The 2.2-kilobase latency-associated transcript of herpes simplex virus type 2 does not modulate viral replication, reactivation, or establishment of latency in transgenic mice. J Virol (2001) 1.04
Using centralized laboratory data to monitor trends in herpes simplex virus type 1 and 2 infection in British Columbia and the changing etiology of genital herpes. Can J Public Health (2011) 0.96
Cloning of full length genome of varicella-zoster virus vaccine strain into a bacterial artificial chromosome and reconstitution of infectious virus. Vaccine (2007) 0.95
Cloning of the herpes simplex virus type 1 genome as a novel luciferase-tagged infectious bacterial artificial chromosome. Arch Virol (2011) 0.92
Cloning human herpes virus 6A genome into bacterial artificial chromosomes and study of DNA replication intermediates. Proc Natl Acad Sci U S A (2009) 0.92
DNA immunization with a herpes simplex virus 2 bacterial artificial chromosome. Virology (2004) 0.84
Reducing the risk of transmitting genital herpes: advances in understanding and therapy. Curr Med Res Opin (2005) 0.80
Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector. J Gene Med (2006) 0.77
Cloning of replication-incompetent herpes simplex viruses as bacterial artificial chromosomes to facilitate development of vectors for gene delivery into differentiated neurons. Hum Gene Ther (2006) 0.76
Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature (2011) 2.82
Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood (2010) 2.77
Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood (2006) 2.69
Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci U S A (2004) 2.51
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med (2009) 2.26
A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity (2011) 2.15
Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science (2013) 2.00
Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood (2013) 1.93
Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst (2004) 1.80
An acutely and latently expressed herpes simplex virus 2 viral microRNA inhibits expression of ICP34.5, a viral neurovirulence factor. Proc Natl Acad Sci U S A (2008) 1.77
Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol (2005) 1.68
Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain (2006) 1.53
Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread. Cell (2006) 1.51
Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. PLoS Pathog (2012) 1.49
Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Virol (2003) 1.48
Serological diagnosis of human herpes simplex virus type 1 and 2 infections by luciferase immunoprecipitation system assay. Clin Vaccine Immunol (2009) 1.46
Schistosoma mansoni infection in eosinophil lineage-ablated mice. Blood (2006) 1.42
Generation of Epstein-Barr Virus (EBV)-immortalized B cell lines. Curr Protoc Immunol (2007) 1.30
Rapid, simple, quantitative, and highly sensitive antibody detection for lyme disease. Clin Vaccine Immunol (2010) 1.25
Painful pathways induced by TLR stimulation of dorsal root ganglion neurons. J Immunol (2011) 1.24
The varicella-zoster virus open reading frame 63 latency-associated protein is critical for establishment of latency. J Virol (2004) 1.22
Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol (2007) 1.22
Identification of viral microRNAs expressed in human sacral ganglia latently infected with herpes simplex virus 2. J Virol (2009) 1.21
Varicella-Zoster virus IE63, a major viral latency protein, is required to inhibit the alpha interferon-induced antiviral response. J Virol (2007) 1.18
Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis (2009) 1.17
Varicella-zoster virus open reading frame 2 encodes a membrane phosphoprotein that is dispensable for viral replication and for establishment of latency. J Virol (2002) 1.17
Varicella-zoster virus ORF4 latency-associated protein is important for establishment of latency. J Virol (2005) 1.16
Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. Blood (2003) 1.14
Binding of FADD and caspase-8 to molluscum contagiosum virus MC159 v-FLIP is not sufficient for its antiapoptotic function. J Virol (2002) 1.09
Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine (2008) 1.08
Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis. J Biol Chem (2009) 1.07
Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci U S A (2004) 1.06
Varicella-zoster virus immediate-early 63 protein interacts with human antisilencing function 1 protein and alters its ability to bind histones h3.1 and h3.3. J Virol (2008) 1.06
Varicella-zoster virus (VZV) ORF17 protein induces RNA cleavage and is critical for replication of VZV at 37 degrees C but not 33 degrees C. J Virol (2002) 1.05
Regions of the varicella-zoster virus open reading frame 63 latency-associated protein important for replication in vitro are also critical for efficient establishment of latency. J Virol (2005) 1.05
LIPS arrays for simultaneous detection of antibodies against partial and whole proteomes of HCV, HIV and EBV. Mol Biosyst (2011) 1.04
Interleukin 17 modulates the immune response to vaccinia virus infection. Virology (2002) 1.03
Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers. J Virol (2009) 1.03
Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication. J Virol (2003) 1.03
Detection of EBV genomes in plasmablasts/plasma cells and non-B cells in the blood of most patients with EBV lymphoproliferative disorders by using Immuno-FISH. Blood (2010) 1.03
Increased frequency of EBV-specific effector memory CD8+ T cells correlates with higher viral load in rheumatoid arthritis. J Immunol (2008) 1.02
The NS3 protein of hepatitis C virus induces caspase-8-mediated apoptosis independent of its protease or helicase activities. Virology (2004) 1.02
Varicella-zoster virus open reading frame 21, which is expressed during latency, is essential for virus replication but dispensable for establishment of latency. J Virol (2003) 1.01
Comparison of virus transcription during lytic infection of the Oka parental and vaccine strains of Varicella-Zoster virus. J Virol (2006) 1.01
Perforin and lymphohistiocytic proliferative disorders. Br J Haematol (2005) 0.99
Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice. J Neurovirol (2002) 0.98
Absence or overexpression of the Varicella-Zoster Virus (VZV) ORF29 latency-associated protein impairs late gene expression and reduces VZV latency in a rodent model. J Virol (2006) 0.97
Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge. PLoS Pathog (2011) 0.97
Use of a rodent model to show that varicella-zoster virus ORF61 is dispensable for establishment of latency. J Med Virol (2003) 0.95
The number of herpes simplex virus-infected neurons and the number of viral genome copies per neuron correlate with the latent viral load in ganglia. Virology (2007) 0.95
Severe viral infections and primary immunodeficiencies. Clin Infect Dis (2011) 0.94
Feline calicivirus replication induces apoptosis in cultured cells. Virus Res (2003) 0.93
Diverse herpes simplex virus type 1 thymidine kinase mutants in individual human neurons and Ganglia. J Virol (2007) 0.93
Varicella-Zoster virus ORF12 protein triggers phosphorylation of ERK1/2 and inhibits apoptosis. J Virol (2012) 0.93
Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J Infect Dis (2012) 0.93
Evidence of prior exposure to human bocavirus as determined by a retrospective serological study of 404 serum samples from adults in the United States. Clin Vaccine Immunol (2009) 0.92
Langat flavivirus protease NS3 binds caspase-8 and induces apoptosis. J Virol (2002) 0.92
Varicella-zoster virus open reading frame 47 (ORF47) protein is critical for virus replication in dendritic cells and for spread to other cells. Virology (2005) 0.91
Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS). Exp Hematol (2009) 0.91
Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome. Am J Hematol (2007) 0.89
The amino terminus of varicella-zoster virus (VZV) glycoprotein E is required for binding to insulin-degrading enzyme, a VZV receptor. J Virol (2007) 0.89
Herpes zoster. N Engl J Med (2013) 0.88
Comparison of methods for detection of vaccinia virus in patient specimens. J Clin Microbiol (2005) 0.87
Triad of severe abdominal pain, inappropriate antidiuretic hormone secretion, and disseminated varicella-zoster virus infection preceding cutaneous manifestations after hematopoietic stem cell transplantation: utility of PCR for early recognition and therapy. Pediatr Infect Dis J (2008) 0.87
Varicella-zoster virus ORF12 protein activates the phosphatidylinositol 3-kinase/Akt pathway to regulate cell cycle progression. J Virol (2012) 0.86
Varicella-zoster virus expressing HSV-2 glycoproteins B and D induces protection against HSV-2 challenge. Vaccine (2004) 0.86
Downregulation of varicella-zoster virus (VZV) immediate-early ORF62 transcription by VZV ORF63 correlates with virus replication in vitro and with latency. J Virol (2006) 0.86
Human herpesvirus-6-associated acute lymphadenitis in immunocompetent adults. Mod Pathol (2004) 0.86
Ascorbic acid kills Epstein-Barr virus positive Burkitt lymphoma cells and Epstein-Barr virus transformed B-cells in vitro, but not in vivo. Leuk Lymphoma (2012) 0.86
The capacity of UL49.5 proteins to inhibit TAP is widely distributed among members of the genus Varicellovirus. J Virol (2010) 0.85
The challenge of developing a herpes simplex virus 2 vaccine. Expert Rev Vaccines (2012) 0.85
LAT region factors mediating differential neuronal tropism of HSV-1 and HSV-2 do not act in trans. PLoS One (2012) 0.85
Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection. Pediatr Blood Cancer (2009) 0.85
Rhesus and human cytomegalovirus glycoprotein L are required for infection and cell-to-cell spread of virus but cannot complement each other. J Virol (2010) 0.83
Insulin degrading enzyme induces a conformational change in varicella-zoster virus gE, and enhances virus infectivity and stability. PLoS One (2010) 0.82
Optimal treatment for chronic active Epstein-Barr virus disease. Pediatr Transplant (2009) 0.81
Use of a universal virus detection assay to identify human metapneumovirus in a hematopoietic stem cell transplant recipient with pneumonia of unknown origin. J Clin Virol (2009) 0.81
Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. J Immunol (2011) 0.81
Oropharyngeal shedding of Epstein-Barr virus in the absence of circulating B cells. J Infect Dis (2008) 0.81